DGX Quote, Financials, Valuation and Earnings

Danaher Corp. has a net margin of 9.13% compared to Quest Diagnostics, Inc.'s net margin of 15%. Quest Diagnostics, Inc.'s return on equity of 14.33% beat Danaher Corp.'s return on equity of 6.87%.

Quest Diagnostics, Inc. has a consensus price target of $198.06, signalling upside risk potential of 12.59%. On the other hand Danaher Corp. has an analysts' consensus of $258.09 which suggests that it could grow by 11.5%. Given that Quest Diagnostics, Inc. has higher upside potential than Danaher Corp., analysts believe Quest Diagnostics, Inc. is more attractive than Danaher Corp..

Quest Diagnostics, Inc. has a beta of 0.618, which suggesting that the stock is 38.214% less volatile than S&P 500. In comparison Danaher Corp. has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.801%.

Quest Diagnostics, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 1.79%. Danaher Corp. offers a yield of 0.53% to investors and pays a quarterly dividend of $0.32 per share. Quest Diagnostics, Inc. pays 39.15% of its earnings as a dividend. Danaher Corp. pays out 20.42% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics, Inc. quarterly revenues are $2.8B, which are smaller than Danaher Corp. quarterly revenues of $6.1B. Quest Diagnostics, Inc.'s net income of $257M is lower than Danaher Corp.'s net income of $908M. Notably, Quest Diagnostics, Inc.'s price-to-earnings ratio is 20.64x while Danaher Corp.'s PE ratio is 47.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics, Inc. is 1.83x versus 6.87x for Danaher Corp.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of 9.13% compared to Quest Diagnostics, Inc.'s net margin of -2.3%. Quest Diagnostics, Inc.'s return on equity of 14.33% beat EXACT Sciences Corp.'s return on equity of -38%.

Quest Diagnostics, Inc. has a consensus price target of $198.06, signalling upside risk potential of 12.59%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.98%. Given that Quest Diagnostics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Quest Diagnostics, Inc. is more attractive than EXACT Sciences Corp..

Quest Diagnostics, Inc. has a beta of 0.618, which suggesting that the stock is 38.214% less volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Quest Diagnostics, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 1.79%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics, Inc. pays 39.15% of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics, Inc. quarterly revenues are $2.8B, which are larger than EXACT Sciences Corp. quarterly revenues of $850.7M. Quest Diagnostics, Inc.'s net income of $257M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Quest Diagnostics, Inc.'s price-to-earnings ratio is 20.64x while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics, Inc. is 1.83x versus 6.18x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health, Inc. has a net margin of 9.13% compared to Quest Diagnostics, Inc.'s net margin of -34.97%. Quest Diagnostics, Inc.'s return on equity of 14.33% beat Guardant Health, Inc.'s return on equity of -8518.58%.

Quest Diagnostics, Inc. has a consensus price target of $198.06, signalling upside risk potential of 12.59%. On the other hand Guardant Health, Inc. has an analysts' consensus of $114.05 which suggests that it could grow by 11.4%. Given that Quest Diagnostics, Inc. has higher upside potential than Guardant Health, Inc., analysts believe Quest Diagnostics, Inc. is more attractive than Guardant Health, Inc..

Quest Diagnostics, Inc. has a beta of 0.618, which suggesting that the stock is 38.214% less volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.579, suggesting its more volatile than the S&P 500 by 57.876%.

Quest Diagnostics, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 1.79%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics, Inc. pays 39.15% of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics, Inc. quarterly revenues are $2.8B, which are larger than Guardant Health, Inc. quarterly revenues of $265.2M. Quest Diagnostics, Inc.'s net income of $257M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, Quest Diagnostics, Inc.'s price-to-earnings ratio is 20.64x while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics, Inc. is 1.83x versus 14.08x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings, Inc. has a net margin of 9.13% compared to Quest Diagnostics, Inc.'s net margin of 7.34%. Quest Diagnostics, Inc.'s return on equity of 14.33% beat Labcorp Holdings, Inc.'s return on equity of 10.25%.

Quest Diagnostics, Inc. has a consensus price target of $198.06, signalling upside risk potential of 12.59%. On the other hand Labcorp Holdings, Inc. has an analysts' consensus of $299.71 which suggests that it could grow by 17.78%. Given that Labcorp Holdings, Inc. has higher upside potential than Quest Diagnostics, Inc., analysts believe Labcorp Holdings, Inc. is more attractive than Quest Diagnostics, Inc..

Quest Diagnostics, Inc. has a beta of 0.618, which suggesting that the stock is 38.214% less volatile than S&P 500. In comparison Labcorp Holdings, Inc. has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.121%.

Quest Diagnostics, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 1.79%. Labcorp Holdings, Inc. offers a yield of 1.13% to investors and pays a quarterly dividend of $0.72 per share. Quest Diagnostics, Inc. pays 39.15% of its earnings as a dividend. Labcorp Holdings, Inc. pays out 32.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics, Inc. quarterly revenues are $2.8B, which are smaller than Labcorp Holdings, Inc. quarterly revenues of $3.6B. Quest Diagnostics, Inc.'s net income of $257M is lower than Labcorp Holdings, Inc.'s net income of $261.5M. Notably, Quest Diagnostics, Inc.'s price-to-earnings ratio is 20.64x while Labcorp Holdings, Inc.'s PE ratio is 24.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics, Inc. is 1.83x versus 1.55x for Labcorp Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.